Link between high cholesterol and better memory

What's bad for your ticker may be good for your bean, according to a research from a team of scientists at Boston University.

The team looked at 18 years of data from the long-running Framingham Heart Study and found an association between naturally high levels of blood cholesterol and better mental functioning. The results were recently published in the journal Psychosomatic Medicine.

The research team, led by BU Department of Mathematics and Statistics Research Assistant Professor Penelope Elias (now at University of Maine at Orono) and including Merrill Elias, research professor of epidemiology in BU's Mathematics and Statistics Department, found a link between naturally occurring high cholesterol and modestly better mental function in areas such as visual organization, memory, attention, and concentration. Unlike previous studies, the current research isolated blood cholesterol from other well-known risk factors.

Along with high blood pressure, diabetes, and hypertension, high cholesterol has long been known as a risk factor for heart disease and stroke. However, the results of the new study showed that the higher the natural level of cholesterol, the better participants did on tests of mental ability. High cholesterol was defined as > 240 mg/dL as measured in blood samples.

Less than two percent of the participants were being treated with anti-cholesterol medication. Anti-cholesterol medications and diets as well as risk factors such as smoking and alcohol consumption were controlled for statistically.

Cholesterol is important for brain development in infants and plays a role in how neurons work in adults. High blood cholesterol level is still considered a risk factor for stroke and heart disease, however, and physicians may decide that those risks outweigh any modest benefits for cognitive function. Scientists have not yet determined whether lowering cholesterol with medication will influence mental functioning.

"The result of lowering cholesterol with current medications may be very different from naturally low cholesterol," said Merrill Elias. "We certainly need to evaluate what effect lowering cholesterol with medication will have. We can't yet generalize the results of our study to people treated with cholesterol-lowering drugs."

The authors emphasize that these findings do not provide a justification for people to disregard their physician's recommendations with regard to medications for high cholesterol.

Researchers next must consider individual elements of total blood cholesterol, such as LDL (low-density lipoprotein, commonly referred to as "bad" cholesterol), HDL (high-density lipoprotein, or "good" cholesterol), and triglycerides, and whether one or more of these elements is responsible for the results.

The Framingham Heart Study began in 1955 and has followed three generations of participants, measuring the incidence of cardiovascular disease and stroke and determining the risk of various associated factors. The study, based in Framingham, Mass., started before cardiovascular risk factors for heart disease and stroke were well understood and before patients were routinely treated with cholesterol-lowering medications.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients